Skip to main content
. 2021 Mar 25;39(15):1650–1659. doi: 10.1200/JCO.20.02262

FIG 3.

FIG 3.

Continuous remission, OS, and EFS. (A) OS and EFS among patients with B-cell acute lymphoblastic leukemia, starting from CAR infusion at day 0. (B) OS, (C) EFS among patients who received Flu/Cy–based pre-CAR T-cell lymphodepletion versus those who did not. (D) OS, (E) EFS among patients who had an M2 marrow (≥ 5% marrow disease) or higher compared with those who had an M1 marrow (< 5%) disease. (F) OS and EFS among patients who proceeded to a consolidative allogeneic HSCT, from HSCT day 0. CAR, chimeric antigen receptor; EFS, event-free survival; Flu/Cy, fludarabine/cyclophosphamide; HSCT, hematopoietic stem-cell transplant; OS, overall survival.